Unknown

Dataset Information

0

Fc-engineered antibody therapeutics with improved efficacy against COVID-19.


ABSTRACT: Monoclonal antibodies (mAbs) with neutralizing activity against SARS-CoV-2 have demonstrated clinical benefit in cases of mild to moderate SARS-CoV-2 infection, substantially reducing the risk for hospitalization and severe disease1-4. Treatment generally requires the administration of high doses of these mAbs with limited efficacy in preventing disease complications or mortality among hospitalized COVID-19 patients5. Here we report the development and evaluation of Fc-optimized anti-SARS-CoV-2 mAbs with superior potency to prevent or treat COVID-19 disease. In several animal models of COVID-19 disease6,7, we demonstrate that selective engagement of activating FcγRs results in improved efficacy in both preventing and treating disease-induced weight loss and mortality, significantly reducing the dose required to confer full protection upon SARS-CoV-2 challenge and treatment of pre-infected animals. Our results highlight the importance of FcγR pathways in driving antibody-mediated antiviral immunity, while excluding any pathogenic or disease-enhancing effects of FcγR engagement of anti-SARS-CoV-2 antibodies upon infection. These findings have important implications for the development of Fc-engineered mAbs with optimal Fc effector function and improved clinical efficacy against COVID-19 disease.

SUBMITTER: Ravetch J 

PROVIDER: S-EPMC8168397 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC9038156 | biostudies-literature
| S-EPMC7387268 | biostudies-literature
| S-EPMC8067572 | biostudies-literature
| S-EPMC9272907 | biostudies-literature
| S-EPMC7454247 | biostudies-literature
| S-EPMC8744556 | biostudies-literature
| S-EPMC7685319 | biostudies-literature
| S-EPMC5777970 | biostudies-literature
| S-EPMC1389705 | biostudies-literature
| S-EPMC7655984 | biostudies-literature